Oxygen regulation of TET enzymes.
5hmC
TET
cancer
hypoxia
immunotherapy
α-KG-dependent enzymes
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
23
12
2020
received:
29
10
2020
accepted:
04
01
2021
pubmed:
8
1
2021
medline:
12
1
2022
entrez:
7
1
2021
Statut:
ppublish
Résumé
Hypoxia has a significant impact on many physiological and pathological processes. Over the recent years, its role in modulation of epigenetic remodelling has also become clearer. In cancer, low oxygen environments and aberrant epigenomes often go hand in hand, and changes in DNA methylation are now commonly recognised as potential outcome indicators. TET (ten-eleven translocation) family enzymes are alpha-ketoglutarate-, iron- and oxygen-dependent DNA demethylases and are key players in these processes. Although TETs have historically been considered tumour suppressors, recent studies suggest that their functions in cancer might not be straightforward. Recently, inhibition of TETs has been reported to have positive impact in cancer immunotherapy and vaccination studies. This underlines the current interest in developing targeted pharmaceutical inhibitors of these enzymes. Here, we will survey the complexity of TET roles in cancer, and its hypoxic modulation, as well as highlight the potential of these enzymes as therapeutic targets.
Substances chimiques
Mixed Function Oxygenases
EC 1.-
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7143-7161Subventions
Organisme : Wellcome Trust
ID : 214283/Z/18/Z
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
Wigerup C, Påhlman S & Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164, 152-169.
Wang W, Winlove CP & Michel CC (2003) Oxygen partial pressure in outer layers of skin of human finger nail folds. J Physiol 549, 855-863.
Dings J, Meixensberger J, Jäger A & Roosen K (1998) Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery 43, 1082-1094.
Carreau A, Hafny-Rahbi BE, Matejuk A, Grillon C & Kieda C (2011) Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 15, 1239-1253.
McKeown SR (2014) Defining normoxia, physoxia and hypoxia in tumours-Implications for treatment response. Br J Radiol 87, 20130676.
Patiar S & Harris AL (2006) Role of hypoxia-inducible factor-1α as a cancer therapy target. Endocr Relat Cancer 13, S61-S75.
Bristow RG & Hill RP (2008) Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8, 180-192.
Olcina MM, Foskolou IP, Anbalagan S, Senra JM, Pires IM, Jiang Y, Ryan AJ & Hammond EM (2013) Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol Cell 52, 758-766.
Foskolou IP, Jorgensen C, Leszczynska KB, Olcina MM, Tarhonskaya H, Haisma B, D’Angiolella V, Myers WK, Domene C, Flashman E et al. (2017) Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication. Mol Cell 66, 206-220.e9.
Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, Span PN, O’Neill EE, Buffa FM & Hammond EM (2015) Hypoxia-induced P53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest 125, 2385-2398.
Weidemann A & Johnson RS (2008) Biology of HIF-1 α. Cell Death Differ 15, 621-627.
Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH & Gassmann M (2001) Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 15, 1312-1314.
Bruick RK & McKnight SL (2001) A conserved family of Prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS & Kaelin WG Jr (2001) HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468.
Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ et al. (2001) Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472.
Sim J, Cowburn AS, Palazon A, Madhu B, Tyrakis PA, Macías D, Bargiela DM, Pietsch S, Gralla M, Evans CE et al. (2018) The factor inhibiting HIF asparaginyl hydroxylase regulates oxidative metabolism and accelerates metabolic adaptation to hypoxia. Cell Metab 27, 898-913.e7.
Mahon PC, Hirota K & Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15, 2675-2686.
Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML & Bruick RK (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16, 1466-1471.
Islam MdS, Leissing TM, Chowdhury R, Hopkinson RJ & Schofield CJ (2018) 2-oxoglutarate-dependent oxygenases. Annu Rev Biochem 87, 585-620.
Goda N, Dozier SJ & Johnson RS (2003) HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid Redox Signal 5, 467-473.
Macias D, Cowburn AS, Torres-Torrelo H, Ortega-Sáenz P, López-Barneo J & Johnson RS (2018) HIF-2α is essential for carotid body development and function. eLife 7, e34681.
Thompson AAR, Dickinson RS, Murphy F, Thomson JP, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Mirchandani A et al. (2017) Hypoxia determines survival outcomes of bacterial infection through HIF-1α-dependent reprogramming of leukocyte metabolism. Sci Immunol 2, eaal2861.
Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li J-L et al. (2014) Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep 9, 349-365.
Esteller M (2008) Epigenetics in cancer. N Engl J Med 358, 1148-1159.
Choudhry H & Harris AL (2018) Advances in hypoxia-inducible factor biology. Cell Metab 27, 281-298.
Beyer S, Kristensen MM, Jensen KS, Johansen JV & Staller P (2008) The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283, 36542-36552.
Chen S, Yin C, Lao T, Liang D, He D, Wang C & Sang N (2015) AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol. Cell Cycle 14, 2520-2536.
Koslowski M, Luxemburger U, Türeci Ö & Sahin U (2011) Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α. Oncogene 30, 876-882.
Camuzi D, de Amorim ÍSS, Ribeiro Pinto LF, Oliveira Trivilin L, Mencalha AL & Soares Lima SC (2019) Regulation is in the air: the relationship between hypoxia and epigenetics in cancer. Cells 8, 300. https://doi.org/10.3390/cells8040300
He C (2010) Grand challenge commentary: RNA epigenetics? Nat Chem Biol 6, 863-865.
Fry NJ, Law BA, Ilkayeva OR, Holley CL & Mansfield KD (2017) N 6 -methyladenosine is required for the hypoxic stabilization of specific MRNAs. RNA 23, 1444-1455.
Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X & Semenza GL (2016) Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated M6A-demethylation of NANOG MRNA. Proc Natl Acad Sci USA 113, E2047-E2056.
Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME et al. (2019) Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathol 138, 1053-1074.
Ivanova IG, Park CV & Kenneth NS (2019) Translating the hypoxic response-the role of HIF protein translation in the cellular response to low oxygen. Cells 8, 114.
El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TGP, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D et al. (2015) Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell 27, 682-697.
Ivanova IG, Park CV, Yemm AI & Kenneth NS (2018) PERK/EIF2α signaling inhibits HIF-induced gene expression during the unfolded protein response via YB1-dependent regulation of HIF1α translation. Nucleic Acids Res 46, 3878-3890.
Matsumoto K & Bay B-H (2005) Significance of the Y-Box proteins in human cancers. J Mol Genet Med 1, 11-17.
Maurya PK, Mishra A, Yadav BS, Singh S, Kumar P, Chaudhary A, Srivastava S, Murugesan SN & Mani A (2017) Role of Y Box protein-1 in cancer: as potential biomarker and novel therapeutic target. J Cancer 8, 1900-1907.
Jürchott K, Kuban R-J, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kiełbasa SM, Ungethüm U, Lund P et al. (2010) Identification of Y-Box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 6, e1001231.
Hancock RL, Dunne K, Walport LJ, Flashman E & Kawamura A (2015) Epigenetic regulation by histone demethylases in hypoxia. Epigenomics 7, 791-811.
Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST & Downing JR (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(Q22;Q23). Leukemia 17, 637-641.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.
Yamagata K & Kobayashi A (2017) The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36. J Biochem 161, 327-330.
Zhang H, Zhang X, Clark E, Mulcahey M, Huang S & Shi YG (2010) TET1 Is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 20, 1390-1393.
Xu Y, Xu C, Kato A, Tempel W, Abreu JG, Bian C, Hu Y, Hu D, Zhao B, Cerovina T et al. (2012) Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for xenopus eye and neural development. Cell 151, 1200-1213.
Ko M, An J, Bandukwala HS, Chavez L, Äijö T, Pastor WA, Segal MF, Li H, Koh KP, Lähdesmäki H et al. (2013) Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497, 122-126.
Liu D, Li G & Zuo Y (2019) Function determinants of TET proteins: the arrangements of sequence motifs with specific codes. Brief Bioinform 20, 1826-1835.
Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H et al. (2015) WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell 57, 662-673.
Chen L-L, Lin H-P, Zhou W-J, He C-X, Zhang Z-Y, Cheng Z-L, Song J-B, Liu P, Chen X-Y, Xia Y-K et al. (2018) SNIP1 recruits TET2 to regulate C-MYC target genes and cellular DNA damage response. Cell Rep 25, 1485-1500.e4.
Wang Y & Zhang Y (2014) Regulation of TET protein stability by calpains. Cell Rep 6, 278-284.
Zhang J, Tan P, Guo L, Gong J, Ma J, Li J, Lee M, Fang S, Jing J, Johnson G et al. (2019) P53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance. Oncogene 38, 1905-1919.
Lv L, Wang Q, Xu Y, Tsao L-C, Nakagawa T, Guo H, Su L & Xiong Y (2018) Vpr targets TET2 for degradation by CRL4VprBP E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Mol Cell 70, 961-970.e5.
Yang J, Bashkenova N, Zang R, Huang X & Wang J (2020) The roles of TET family proteins in development and stem cells. Development 147, dev183129. https://doi.org/10.1242/dev.183129
Simon MC & Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9, 285-296.
Iqbal K, Jin S-G, Pfeifer GP & Szabó PE (2011) Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci USA 108, 3642-3647.
Wossidlo M, Nakamura T, Lepikhov K, Marques CJ, Zakhartchenko V, Boiani M, Arand J, Nakano T, Reik W & Walter J (2011) 5-hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2, 241.
Rasmussen KD & Helin K (2016) Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 30, 733-750.
Khoueiry R, Sohni A, Thienpont B, Luo X, Velde JV, Bartoccetti M, Boeckx B, Zwijsen A, Rao A, Lambrechts D et al. (2017) Lineage-specific functions of TET1 in the postimplantation mouse embryo. Nat Genet 49, 1061-1072.
Zhang W, Xia W, Wang Q, Towers AJ, Chen J, Gao R, Zhang Y, Yen C, Lee AY, Li Y et al. (2016) Isoform switch of TET1 regulates DNA demethylation and mouse development. Mol Cell 64, 1062-1073.
Liu N, Wang M, Deng W, Schmidt CS, Qin W, Leonhardt H & Spada F (2013) Intrinsic and extrinsic connections of Tet3 dioxygenase with CXXC zinc finger modules. PLoS One 8, e62755.
Sohni A, Bartoccetti M, Khoueiry R, Spans L, Vande Velde J, De Troyer L, Pulakanti K, Claessens F, Rao S & Koh KP (2015) Dynamic switching of active promoter and enhancer domains regulates Tet1 and Tet2 expression during cell state transitions between pluripotency and differentiation. Mol Cell Biol 35, 1026-1042.
Kallin EM, Rodríguez-Ubreva J, Christensen J, Cimmino L, Aifantis I, Helin K, Ballestar E & Graf T (2012) Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol Cell 48, 266-276.
Dai H-Q, Wang B-A, Yang L, Chen J-J, Zhu G-C, Sun M-L, Ge H, Wang R, Chapman DL, Tang F et al. (2016) TET-mediated DNA demethylation controls gastrulation by regulating lefty-nodal signalling. Nature 538, 528-532.
Bogdanović O, Smits AH, de la Calle Mustienes E, Tena JJ, Ford E, Williams R, Senanayake U, Schultz MD, Hontelez S, van Kruijsbergen I et al. (2016) Active DNA demethylation at enhancers during the vertebrate phylotypic period. Nat Genet 48, 417-426.
Gu T-P, Guo F, Yang H, Wu H-P, Xu G-F, Liu W, Xie Z-G, Shi L, He X, Jin S et al. (2011) The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477, 606-610.
Kang J, Lienhard M, Pastor WA, Chawla A, Novotny M, Tsagaratou A, Lasken RS, Thompson EC, Surani MA, Koralov SB et al. (2015) Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis. Proc Natl Acad Sci USA 112, E4236-E4245.
Dawlaty MM, Ganz K, Powell BE, Hu Y-C, Markoulaki S, Cheng AW, Gao Q, Kim J, Choi S-W, Page DC et al. (2011) Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 9, 166-175.
Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X et al. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24.
Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW, Gao Q, Powell BE, Li Z, Xu M et al. (2013) Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell 24, 310-323.
Hirsilä M, Koivunen P, Günzler V, Kivirikko KI & Myllyharju J (2003) Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278, 30772-30780.
Cascella B, & Mirica LM. (2012) Kinetic analysis of iron-dependent histone demethylases: α-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells. Biochem 51(44), 8699-8701. https://doi.org/10.1021/bi3012466
Thienpont B, Steinbacher J, Zhao H, D’Anna F, Kuchnio A, Ploumakis A, Ghesquière B, Van Dyck L, Boeckx B, Schoonjans L et al. (2016) Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537, 63-68.
Burr S, Caldwell A, Chong M, Beretta M, Metcalf S, Hancock M, Arno M, Balu S, Kropf VL, Mistry RK et al. (2018) Oxygen gradients can determine epigenetic asymmetry and cellular differentiation via differential regulation of Tet activity in embryonic stem cells. Nucleic Acids Res 46, 1210-1226.
Alivand MR, Soheili Z-S, Pornour M, Solali S & Sabouni F (2017) Novel epigenetic controlling of hypoxia pathway related to overexpression and promoter hypomethylation of TET1 and TET2 in RPE cells. J Cell Biochem 118, 3193-3204.
Smith KA, Waypa GB & Schumacker PT (2017) Redox signaling during hypoxia in mammalian cells. Redox Biol 13, 228-234.
Minor EA, Court BL, Young JI & Wang G (2013) Ascorbate induces Ten-Eleven Translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem 288, 13669-13674.
Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M et al. (2017) Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079-1095.e20.
Yin R, Mao S-Q, Zhao B, Chong Z, Yang Y, Zhao C, Zhang D, Huang H, Gao J, Li Z et al. (2013) Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 135, 10396-10403.
Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H & Hayashi Y (2002) LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(Q22;Q23). Cancer Res 62, 4075-4080.
Pfeifer GP, Kadam S & Jin S-G (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 6, 10.
Ma L, Qi T, Wang S, Hao M, Sakhawat A, Liang T, Zhang L, Cong X & Huang Y (2019) Tet methylcytosine dioxygenase 1 promotes hypoxic gene induction and cell migration in colon cancer. J Cell Physiol 234, 6286-6297.
Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, Shmulevich I, Sander C & Stuart JM (2013) The cancer genome Atlas pan-cancer analysis project. Nat Genet 45, 1113-1120.
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E et al. (2019) COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 47, D941-D947.
Yang H, Liu Y, Bai F, Zhang J-Y, Ma S-H, Liu J, Xu Z-D, Zhu H-G, Ling Z-Q, Ye D et al. (2013) Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32, 663-669.
Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q et al. (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135-1146.
Fischer AP & Miles SL (2017) Silencing HIF-1α induces TET2 expression and augments ascorbic acid induced 5-hydroxymethylation of DNA in human metastatic melanoma cells. Biochem Biophys Res Comm 490, 176-181.
McCarty G & Loeb DM (2015) Hypoxia-sensitive epigenetic regulation of an antisense-oriented LncRNA controls WT1 expression in myeloid leukemia cells. PLoS One 10, e0119837.
Prasad P, Mittal SA, Chongtham J, Mohanty S & Srivastava T (2017) Hypoxia-mediated epigenetic regulation of stemness in brain tumor cells: TET proteins regulate stemness in hypoxic gliomas. Stem Cells 35, 1468-1478.
Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger RH, Cohn SL, Nanduri J et al. (2014) TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep 7, 1343-1352.
Wu M-Z, Chen S-F, Nieh S, Benner C, Ger L-P, Jan C-I, Ma L, Chen C-H, Hishida T, Chang H-T et al. (2015) Hypoxia drives breast tumor malignancy through a TET-TNFα-P38-MAPK signaling axis. Cancer Res 75, 3912-3924.
Lin G, Sun W, Yang Z, Guo J, Liu H & Liang J (2017) Hypoxia induces the expression of TET enzymes in HepG2 cells. Oncol Lett 14, 6457-6462.
Tsai Y-P, Chen H-F, Chen S-Y, Cheng W-C, Wang H-W, Shen Z-J, Song C, Teng S-C, He C & Wu K-J (2014) TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator. Genome Biol 15, 513.
Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kwak C et al. (2019) Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. eLife 8, e50663.
Pan W, Zhu S, Qu K, Meeth K, Cheng J, He K, Ma H, Liao Y, Wen X, Roden C et al. (2017) The DNA methylcytosine dioxygenase Tet2 sustains the immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity 47, 284-297.e5.
Collignon E, Canale A, Wardi CA, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A et al. (2018) Immunity drives TET1 regulation in cancer through NF-ΚB. Sci Adv 4, eaap7309.
Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C et al. (2015) TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 16, 653-662.
Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M-H et al. (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38.
Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB & Rao A (2011) Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 108, 14566-14571.
Ito K, Lee J, Chrysanthou S, Zhao Y, Josephs K, Sato H, Teruya-Feldstein J, Zheng D, Dawlaty MM & Ito K (2019) Non-catalytic roles of Tet2 are essential to regulate hematopoietic stem and progenitor cell homeostasis. Cell Rep 28, 2480-2490.e4.
An J, González-Avalos E, Chawla A, Jeong M, López-Moyado IF, Li W, Goodell MA, Chavez L, Ko M & Rao A (2015) Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun 6, 10071.
Kaech SM & Ahmed R (2001) Memory CD8 + T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2, 415-422.
Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C & Tanaka H (2005) TCR engagement increases hypoxia-inducible factor-1α protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol 174, 7592-7599.
Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, Johnson RS & Goldrath AW (2013) Hypoxia-inducible factors enhance the effector responses of CD8 + T cells to persistent antigen. Nat Immunol 14, 1173-1182.
Palazon A, Goldrath AW, Nizet V & Johnson RS (2014) HIF Transcription factors, inflammation, and immunity. Immunity 41, 518-528.
Phan AT, Doedens AL, Palazon A, Tyrakis PA, Cheung KP, Johnson RS & Goldrath AW (2016) Constitutive glycolytic metabolism supports CD8 + T cell effector memory differentiation during viral infection. Immunity 45, 1024-1037.
Pearce EL (2010) Metabolism in T cell activation and differentiation. Curr Opin Immunol 22, 314-320.
Buck MD, O’Sullivan D & Pearce EL (2015) T cell metabolism drives immunity. J Exp Med 212, 1345-1360.
Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, Ras C, Seifar RM, van Minderhout I, Cornelisse CJ, Hogendoorn PC, Breuning MH, Suijker J et al. (2015) Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget 6, 38777-38788.
Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen J, Kaelin WG, Godley LA & Koivunen P (2016) Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J Biol Chem 291, 4256-4265.
Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y et al. (2012) Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26, 1326-1338.
Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa ASH, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MGB et al. (2016) Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537, 544-547.
Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
Intlekofer AM, Dematteo RG, Venneti S, Finley LWS, Lu C, Judkins AR, Rustenburg AS, Grinaway PB, Chodera JD, Cross JR et al. (2015) Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab 22, 304-311.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao M-T et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30.
Tyrakis PA, Palazon A, Macias D, Lee KL, Phan AT, Veliça P, You J, Chia GS, Sim J, Doedens A et al. (2016) S -2-Hydroxyglutarate regulates CD8 + T-lymphocyte fate. Nature 540, 236-241.
Foskolou IP, Barbieri L, Vernet A, Bargiela D, Cunha PP, Velica P, Suh E, Pietsch S, Matuleviciute R, Rundqvist H et al. (2020) The S Enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. Blood Adv 4, 4483-4493.
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307-312.
Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA & Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115, 1616-1626.
Gattinoni L, Klebanoff CA & Restifo NP (2012) Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12, 671-684.
Lee M, Zeng H, Li J, Han W, Sun D & Huang Y (2018) Disruption of TET2 dioxygenase enhances antitumor efficiency in CD8+ tumor infiltrating lymphocytes. Blood 132, 860.
Carty SA, Gohil M, Banks LB, Cotton RM, Johnson ME, Stelekati E, Wells AD, Wherry EJ, Koretzky GA & Jordan MS (2018) The loss of TET2 promotes CD8 + T cell memory differentiation. J Immunol 200, 82-91.
Zhang J, Zhang S, Wang Y, Cheng H, Hao L, Zhai Y, Zhang Z, An X, Ma X, Zhang X et al. (2017) Effect of TET inhibitor on bovine parthenogenetic embryo development. PLoS One 12, e0189542.
Chua GNL, Wassarman KL, Sun H, Alp JA, Jarczyk EI, Kuzio NJ, Bennett MJ, Malachowsky BG, Kruse M & Kennedy AJ (2019) Cytosine-based TET enzyme inhibitors. ACS Med Chem Lett 10, 180-185.
Singh AK, Zhao B, Liu X, Wang X, Li H, Qin H, Wu X, Ma Y, Horne D & Yu X (2020) Selective targeting of TET catalytic domain promotes somatic cell reprogramming. Proc Natl Acad Sci USA 117, 3621-3626.
Liu S, Jiang J, Li L, Amato NJ, Wang Z & Wang Y (2015) Arsenite targets the zinc finger domains of tet proteins and inhibits tet-mediated oxidation of 5-methylcytosine. Environ Sci Technol 49, 11923-11931.
Yin R, Mo J, Dai J & Wang H (2018) Nickel(II) inhibits the oxidation of DNA 5-methylcytosine in mammalian somatic cells and embryonic stem cells. Metallomics 10, 504-512.
Ma Y, Fu H, Zhang C, Cheng S, Gao J, Wang Z, Jin W, Conde J & Cui D (2016) Chiral antioxidant-based gold nanoclusters reprogram DNA epigenetic patterns. Sci Rep 6, 33436.
Zhu J, Wang K, Li T, Chen J, Xie D, Chang X, Yao J, Wu J, Zhou Q, Jia Y et al. (2017) Hypoxia-induced TET1 facilitates trophoblast cell migration and invasion through HIF1α signaling pathway. Sci Rep 7, 1-11.
Wang J, Zhang D, Du J, Zhou C, Li Z, Liu X, Ouyang G & Xiao W (2017) Tet1 facilitates hypoxia tolerance by stabilizing the HIF-α proteins independent of its methylcytosine dioxygenase activity. Nucleic Acids Res 45, 12700-12714.
Skiles WM, Kester A, Pryor JH, Westhusin ME, Golding MC & Long CR (2018) Oxygen-induced alterations in the expression of chromatin modifying enzymes and the transcriptional regulation of imprinted genes. Gene Expr Patterns 28, 1-11.
Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, Shi YG, Zhu J, Wang P & Xu Y (2013) Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell 155, 1545-1555.
Sehnal D, Rose A, Koca J, Burley S, & Velankar S (2018) Mol*: Towards a Common Library and Tools for Web Molecular Graphics. Workshop on Molecular Graphics and Visual Analysis of Molecular Data, 5 pages.
Burley SK, Berman HM, Bhikadiya C, Bi C, Chen L, Di Costanzo L, Christie C, Dalenberg K, Duarte JM, Dutta S et al. (2019) RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res 47, D464-D474.